Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

25 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Joint modeling of tumor dynamics and progression-free survival in advanced breast cancer: Leveraging data from amcenestrant early phase I-II trials.
Cerou M, Thai HT, Deyme L, Fliscounakis-Huynh S, Comets E, Cohen P, Cartot-Cotton S, Veyrat-Follet C. Cerou M, et al. Among authors: veyrat follet c. CPT Pharmacometrics Syst Pharmacol. 2024 Apr 1. doi: 10.1002/psp4.13128. Online ahead of print. CPT Pharmacometrics Syst Pharmacol. 2024. PMID: 38558299 Free article.
PK/PD modeling analysis for dosing regimen selection of isatuximab as single agent and in combination therapy in patients with multiple myeloma.
Koiwai K, El-Cheikh R, Thai HT, Brillac C, Fau JB, Veyrat-Follet C, Risse ML, van de Velde H, Semiond D, Nguyen L. Koiwai K, et al. Among authors: veyrat follet c. CPT Pharmacometrics Syst Pharmacol. 2021 Aug;10(8):928-940. doi: 10.1002/psp4.12666. Epub 2021 Jul 8. CPT Pharmacometrics Syst Pharmacol. 2021. PMID: 34185964 Free PMC article.
Exposure-response analyses for selection/confirmation of optimal isatuximab dosing regimen in combination with pomalidomide/dexamethasone treatment in patients with multiple myeloma.
Rachedi F, Koiwai K, Gaudel-Dedieu N, Sebastien B, Thai HT, Brillac C, Fau JB, Nguyen L, van de Velde H, Veyrat-Follet C, Semiond D. Rachedi F, et al. Among authors: veyrat follet c. CPT Pharmacometrics Syst Pharmacol. 2022 Jun;11(6):766-777. doi: 10.1002/psp4.12789. Epub 2022 Apr 17. CPT Pharmacometrics Syst Pharmacol. 2022. PMID: 35355430 Free PMC article. Clinical Trial.
Model-based simulation to support the approval of isatuximab alone or with dexamethasone for the treatment of relapsed/refractory multiple myeloma in Japanese patients.
Thai HT, Koiwai K, Shitara Y, Kazama H, Fau JB, Semiond D, Veyrat-Follet C. Thai HT, et al. Among authors: veyrat follet c. CPT Pharmacometrics Syst Pharmacol. 2023 Dec;12(12):1846-1858. doi: 10.1002/psp4.12947. Epub 2023 Mar 31. CPT Pharmacometrics Syst Pharmacol. 2023. PMID: 37002644 Free PMC article.
25 results